Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur
11.07.2023 - Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE 327 (R327), resulting in high peak urine concentrations, as previously demonstrated in a completed . Seite 1
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has successfully dosed its first cohort of both male and female subjects with RECCE 327 (R327) as part of its.